Why Merck's Idenix deal is bad news for Gilead By: CNBC.com News June 09, 2014 at 14:34 PM EDT Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower. Read More >> Related Stocks: AbbVie Bristol-Myers Squibb Gilead Sciences Johnson & Johnson Merck & Co